news)

NEWS

Media Contacts:

Europe

Robert Sutherland
Mobile: +44  7917 551 666
Email: robert.sutherland@seqirus.com

United States

Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com

Asia Pacific

Joanne Cleary
Mobile: +61 428 816 751
Email: Joanne.Cleary@seqirus.com

Seqirus news releases

Seqirus news releases

New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
09 Dec 2019

Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine (TIV)

Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
26 Sep 2019

The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.

Seqirus opens new Centre of Excellence in Amsterdam
23 Sep 2019

New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit.

Seqirus and Laboratoire Arrow sign Distribution Agreement in France
17 Sep 2019

This news release is intended for Health Professional media only.

Seqirus starts on time delivery of flu vaccines to support NHS immunisation programmes across the UK
05 Sep 2019

This news release is intended for Health Professional media only.

Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
31 Aug 2019

Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.

Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference
22 Aug 2019

Seqirus announced it will feature data in 3 presentations and 24 posters on the company’s adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.

Seqirus opens new Italian headquarters
19 Jul 2019

Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena.

Anjana Narain to Lead Seqirus Influenza Vaccines Business
17 Jul 2019

CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its Seqirus business, one of the world’s largest influenza vaccines providers.

Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines
15 Jul 2019

This news release is intended for business and trade media only.

First cell-based quadrivalent influenza vaccine approved for use in Europe
14 Jan 2019

This news release is intended for Health Professional media only.

New Data on Cell-Based Seasonal Influenza Vaccines
16 Nov 2018

This news release is intended for Health Professional media only.

Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
16 Nov 2018

The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.

Seqirus Cell-based Influenza Vaccine Nears European Approval
19 Oct 2018

Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season.

Seqirus Joining UIVI to Advance Universal Flu Vaccine Research
26 Jun 2018

Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research

New PNG Snakebite Project to Improve Access to Antivenoms
17 Apr 2018

The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management system.

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors
12 Apr 2018

Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older

JCVI advocates adjuvanted influenza vaccine for patients aged 65 years and over for 2018-19 influenza season
16 Nov 2017

This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu season in the UK.